Dr Jaime Schneider is a thoracic oncologist at the Massachusetts General Hospital (MGH) in Boston, USA, and an instructor in medicine at Harvard Medical School. She obtained her undergraduate degree from Northwestern University and completed her MD/PhD degrees at the Albert Einstein College of Medicine in New York City. Dr Schneider trained in Internal Medicine at MGH and hematology/oncology at the Dana-Farber Cancer Institute. Dr Schneider’s research focuses on using integrative metabolomics approaches to identify resistance mechanisms in oncogene-driven lung cancer.
Browse specialties
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs
ctDNA and bladder cancer: Current understanding and beyond
ROS1 fusion-positive NSCLC
NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC
Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy
ALK fusion-positive NSCLC: International approaches to management
RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC
COVID-19 & cancer
Conferences